The fraudulence of covid-19 vaccines is on full display, and the evidence is sitting right out in the open. The full FDA approval for Pfizer’s COMIRNATY vaccine contained clinical proof that the&nb…
Vaccines and Related Biological Products Advisory Committee Meeting September 17, 2021
FDA Briefing Document
Application for licensure of a booster dose for COMIRNATY (COVID-19 Vaccine, mRNA)
Although not independently verified by FDA, the post hoc analysis appears to indicate that the incidence of SARS-CoV-2 during the analysis period among 18,727 study participants originally randomized to BNT162b2 (mean of 9.8 months post-Dose 2 at the beginning of the analysis period) was 70.3 cases per 1,000 person-years, compared with an incidence of 51.6 cases per 1,000 person-years among 17,748 study participants originally randomized to placebo and crossed over to BNT162b2 (mean of 4.7 months post-Dose 2 at the beginning of the analysis period). An additional analysis appears to indicate that incidence of COVID-19 generally increased in each group of study participants with increasing time post-Dose 2 at the start of the analysis period. Only 3 severe COVID-19 cases were reported during the analysis period, all of which occurred among study participants originally randomized to BNT162b2.
The reported incidence of COVID-19 among study participants who completed the primary series <4 months prior to the start of the analysis period was 43.4 cases per 1,000 person-years. In contrast, during the blinded, placebo-controlled follow-up period of the study with data cutoff of March 13, 2021 (prior to the Delta variant surge), the incidence of COVID-19 among BNT162b2 recipients in the Evaluable Efficacy Population (nearly 60% of whom had 4 months or more of blinded follow-up post-Dose 2) was 12.6 cases per 1,000 person-years.1 This observation suggests that while waning immunity is one potential factor that may have contributed to the higher incidence breakthrough cases during the Delta variant surge, it is possible that other factors (e.g., dynamics of Delta variant transmission and potential differences in vaccine effectiveness against the Delta variant vs. strains circulating during the placebo-controlled portion of the trial) may also have contributed.
If I'm reading this right. By the way this was on the last page of the report.
You are more likely to catch Covid-19 after being Vaccinated. 1.3% vs 4.3%, Thats 300% increase,
Another Study - Ex-Pfizer Employee Warns Vaccine Increases COVID By Over 300% – The World We Live In
In fact, the vaccines increase viral load in the nostrils of the vaccinated.
Background: Data on breakthrough SARS-CoV-2 Delta variant infections are limited.<br><br>Methods: We studied breakthrough infections among healthcare workers of
Transmission of SARS-CoV-2 Delta Variant Among Vaccinated
Viral loads of breakthrough Delta variant infection cases were 251 times higher than those of cases infected with old strains (Natural Immunity) detected between March-April 2020.